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Abstract: In the course of a structure-based drug discovery program the known anticancer 19 
candidate marimastat was uncovered as a potent inhibitor of an enzyme in nematode cuticle 20 
biogenesis. It was shown to kill Caenorhabditis elegans, and the sheep parasites Haemonchus 21 
contortus and Teladorsagia circumcinta via an entirely novel nematode-specific pathway, 22 
specifically by inhibiting cuticle-remodelling enzymes that the parasites require for the 23 
developmentally essential molting process. This discovery prompted an investigation of the 24 
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compound’s effect on Heligmosomoides polygyrus parasites in a mouse model of helminth 25 
infection. Mice were administered the drug via oral gavage daily from day of infection for a 26 
period of 2 wk. A second group received the drug via intra-peritoneal implantation of an 27 
osmotic minipump for 4 wk. Control groups were administered identical volumes of water by 28 
oral gavage in both cases. Counts of H. polygyrus fecal egg and larval load showed that 29 
marimastat effected a consistent and significant reduction in egg laying, and a consistent but 30 
minor reduction in adult worm load when administered every day, starting on the first day of 31 
infection. However, the drug failed to have any significant effect on egg counts or worm 32 
burdens when administered to mice with established infections. Therefore, marimastat does 33 
not appear to show promise as an anthelmintic in gastrointestinal nematode infections, 34 
although other metalloproteases such as batimastat may prove more effective.  35 
 Pathogenic nematodes are the cause of significant levels of disease in man and 36 
livestock. Over one billion people are infected, the majority living in the developing world, 37 
causing a heavy medical and economic burden (Hotez et al., 2008; Geary, 2012). The gastro-38 
intestinal parasitic nematodes of the trichostrongylidae family infect grazing livestock and are 39 
found worldwide. They cause emaciation, anemia, and even death of the host animal, 40 
resulting in a significant impact on animal welfare as well as economic consequences for the 41 
farmer (Grencis, 2015). Haemonchus contortus is a very common parasite, and in terms of 42 
the global agriculture industry, one of the most pathogenic. Haemonchosis results in large 43 
losses for farmers, particularly those living in warmer climates (Gilleard, 2013). The 44 
incidence and cost of the disease are growing, with the parasite now being found in countries 45 
previously free of the disease, including the U.K. It is thought that a combination of livestock 46 
transportation, climate change and resistance to the anthelmintic drugs used to treat the 47 
condition is the cause of the spread (Kaplan, 2004; Wolstenholme et al., 2004).  48 
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Reports of anthelmintic resistance to multiple drugs in individual parasite species, and 49 
in multiple parasite species across virtually all livestock hosts, are common and growing 50 
(Kaplan and Vidyashankar, 2012). Instances of nematode resistance to 3 different 51 
anthelmintics have now also been documented (Papadopoulos, et al., 2012). The ability of the 52 
parasites to survive treatments that are normally effective at the recommended dose rate is 53 
considered a major threat to the future control of the disease (Shalaby, 2013). There are very 54 
few vaccines available for gastro-intestinal nematode prevention and so new compounds that 55 
affect novel nematode drug targets are urgently required. This is not trivial, as evidenced by 56 
the fact that in the last 25 yr, only 2 new classes of anti-nematode drugs have been found: the 57 
cyclodepsipeptides (Lemmens-Gruber et al., 2009) and the aminoacetonitriles (Kaminsky et 58 
al., 2008).  59 
In nematodes, the cuticle is a collagenous extracellular matrix (ECM) synthesized by 60 
an underlying ectodermal cell layer called the hypodermis that surrounds the body of the 61 
animal. Enzymatic digestion of the cuticle occurs during molting via matrix metalloproteases, 62 
where the cuticle is softened and then shed, ready for the newly synthesized layer (Singh and 63 
Sulston, 1978). The cuticle and the molting process in C. elegans, in particular, have been 64 
examined most thoroughly (Cox et al., 1981; Johnstone, 1994; Kramer, 1994), and it has been 65 
shown that chemical and genetic inhibition of the nematode cuticle moulting process results 66 
in death of the organism (Page et al., 2014).  This molting process involves a specific class of 67 
well-characterized astacin metalloproteases, including the procollagen C-proteinase DPY-31. 68 
Recently, a combined ligand- and structure-based inhibitor approach identified a range of 69 
metalloprotease inhibitors that inhibit DPY-31 in vitro from both the human filarial nematode 70 
Brugia malayi, and the parasitic gastrointestinal nematode of sheep Teladorsagia 71 
circumcincta. In vivo these inhibitors also elicit the severe body morphology defect ‘Dumpy’ 72 
(Dpy; shorter and fatter), a predominantly non-viable phenotype consistent with mutants 73 
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lacking the DPY-31 gene (France et al., 2015). These types of inhibitor also often induce 74 
molting defects, which are often fatal to the organism (Stepek et al., 2015). One of the most 75 
potent of these compounds was marimastat, a broad-spectrum matrix metalloprotease 76 
inhibitor previously studied as an antineoplastic in clinical trials (Vandenbroucke and Libert, 77 
2014; Cathcart et al., 2015).  78 
The nematode H. polygyrus is a natural parasite of rodents (Maizels et al., 2012). It 79 
pursues a direct and entirely enteric life cycle, similar to trichostrongylid nematode of 80 
veterinary importance, entering through the mouth and maturing in the intestine to produce 81 
eggs which are voided with feces. It is a valuable laboratory model as it can establish chronic 82 
infection in different strains of mice (Johnston et al., 2015). The aim of this proof-of-concept 83 
study was to examine the effect of marimastat on GI parasite infection to determine whether 84 
the effects noted in vitro on free-living, filarial and trichostrongylid nematodes would 85 
translate to an in vivo H. polygyrus model of the disease. 86 
Heligmosomoides polygyrus infection. C57BL/6 female mice, aged 6-8 wk, were 87 
infected by oral gavage of 200 H. polygyrus L3 in 200 μl water. The H. polygyrus lifecycle 88 
was maintained and the L3 larvae obtained as previously described in (Johnston et al., 2015). 89 
Oral drug administration: Mice were given marimastat (1 mg/200 μl water) by 90 
gavage daily from the first day of infection (day 0) for 2 wk. On the day of infection, 91 
marimastat gavage was given 4-6 hr following parasite infection.  Control mice received a 92 
gavage containing 200 μl water. Mice then received daily gavages of marimastat or water as 93 
appropriate from days 1-8. At day 14 egg and worm counts were performed.  94 
Minipump administration: Administration of marimastat was effected by 95 
intraperitoneal implantation of an osmotic minipump (ALZET 1004, DURECT Corporation, 96 
Cupertino, CA) which released 110 nl per hour for 4 wk. Minipump implants contained either 97 
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marimastat (42 mg/100 μl 50% DMSO) or vehicle alone (100 μl 50% DMSO). At days 14 98 
and 21 egg counts were performed followed by worm and egg counts on day 28.  99 
Administration of drug to established adult worm infections: Mice infected with 200 100 
H. polygyrus L3 in 200 μl water via oral gavage at day 0, received daily gavages of 101 
marimastat (1 mg/200 μl water) or 200 μl water from days 9-17 of infection. At day 14 and 102 
day 21 egg counts were performed followed by worm and egg counts on day 28. 103 
 The egg burdens of individual mice were assessed by collecting 2-3 fecal pellets for 104 
each H. polygyrus-infected mouse at the specified time intervals. Feces were weighed before 105 
being dissolved in 2 ml PBS followed by the addition of 2 ml saturated sodium chloride 106 
solution. Egg counts were then carried out with the use of a McMaster chamber and the 107 
average number of eggs/g feces calculated per sample. At the end point of each study, the 108 
intestinal adult worms were also counted to give the total worm burden of each individual 109 
mouse; the small intestinal tissues were recovered and total worm burdens enumerated with 110 
the aid of a dissecting microscope 111 
 Effects of oral marimastat administration: Mice infected with H. polygyrus were 112 
exposed to marimastat by oral gavage, and levels of infection measured. After 14 days daily 113 
gavage of marimastat solution, a reduction of almost 50% in eggs was observed (Fig. 1A) 114 
when compared to the control group gavaged with water alone.  However, due to the small 115 
sample size and large variability in the control group, this difference achieved only marginal 116 
statistical significance (p = 0.053). At the same time point, total intestinal worm counts were 117 
performed, however, no effect of marimastat was evident in this measure (Fig. 1B). 118 
Effects of intraperitoneal administration of marimastat: A second route of drug administration 119 
was then tested, by intraperitoneal implantation of an osmotic minipump that continuously 120 
released marimastat over a 4 wk period. Although no effect was evident at day 14 (Fig. 2A) 121 
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modest reductions in egg counts in the marimastat minipump group, compared to control 122 
mice implanted with vehicle-alone minipumps, were observed at both day 21 and day 28 123 
(Fig. 2B, C). These differences were consistent (reducing egg counts by 28% at each time 124 
point) albeit not statistically significant (p = 0.229). In contrast to the outcome of oral 125 
administration, some worm killing effect was also suggested with a 30% reduction, although 126 
not reaching statistical significance (p = 0.312), (Fig. 2D).  127 
Treatment of established adult worm infections: Finally, the effects of marimastat on 128 
an established H. polygyrus population was assessed by oral administration from day 8 of 129 
infection, by which time adult worms are established in the intestinal lumen. Although not 130 
statistically significant, a 40.8% reduction in egg counts was observed (p = 0.170; Fig. 3A). 131 
However, no reduction in adult worm numbers was found (Fig. 3B), indicating that 132 
established adult worm infections may be more resistant to marimastat than nascent ones. 133 
All of the egg counts from the final time points of all 3 experiments (n = 15) were 134 
aggregated to perform a final t-test between the marimastat group and the control group, 135 
which established a statistically significant reduction in egg counts (p = 0.048), with an effect 136 
size of 0.76 (where by convention an effect size of 0.5 is considered medium and 0.8 large 137 
(Sawilowsky, 2009)). 138 
Aggregating the results from all 3 experiments reveals a consistent and statistically 139 
significant reduction in egg counts but an inconsistent and negligible reduction in adult worm 140 
load when the drug marimastat is given to mice during the period of larval invasion and 141 
establishment. Furthermore, although adult worm killing by marimastat is not evident, the 142 
reduction in egg counts suggests that those adult nematodes not killed by the drug are still 143 
experiencing deleterious effects from it.  144 
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Heligmosomoides polygyrus is a murine nematode related to the highly prevalent 145 
trichostrongylids of livestock and is a tractable model for screening novel drug compounds. 146 
In our studies, we noted that both the gavage process and minipump implantation (both 147 
widely used delivery methods in clinical research) increased the susceptibility of mice to 148 
infection, compared to animals experiencing no physical intervention. Stress is well known to 149 
impair immune responses (Joana et al., 2016; Levi et al., 2016), and this confounding effect 150 
may also have reduced the observed potency of the compound. 151 
We have previously reported that marimastat produces deleterious effects on 152 
pathogenic nematodes in vitro (France et al, 2015), and here it shows significant effects on 153 
nematode egg production in an animal model when administered orally from the first day of 154 
infection. However, the drug failed to have any significant effect on egg counts or worm 155 
burdens when administered to mice with established infections, or when administered via 156 
osmotic minipump. Therefore, marimastat does not appear to show promise as an 157 
anthelmintic in gastrointestinal nematode infections. Marimastat is known to be rapidly 158 
metabolized in rodents which may have contributed to the weak worm killing power 159 
observed (Rasmussen and McCann, 1997). The related compound batimastat is known to be 160 
less rapidly metabolized and may show more potency in this particular type of assay; this and 161 
other related compounds previously developed to enhance plasma stability (Hermant et al., 162 
2017) should be investigated.  163 
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 243 
Figure 1. Effects of oral marimastat administration. Mice infected with Heligmosomoides 244 
polygyrus were exposed to marimastat by oral gavage daily for 2 wk, and levels of infection 245 
measured (A) egg count; (B) worm count. Control mice received a gavage containing 200 μl 246 
water.  247 
Figure 2 Effects of intraperitoneal administration of marimastat. An osmotic minipump 248 
released either marimastat or vehicle alone for 4 wk. At days 14 (A) and 21 (B) egg counts 249 
were performed followed by egg and worm counts on day 28 (C, D, respectively). 250 
Figure 3 Treatment of established adult worm infections. Mice infected with 251 
Heligmosomoides polygyrus L3 via oral gavage at day 0 received daily gavages of 252 
marimastat or water from days 9-17 of infection. Results are shown for the worm (A) and egg 253 
(B) counts performed on day 28. 254 
